Floatz logo

Bms-907351

Gastroesophageal Cancer

Novartis PharmaceuticalsPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

47 Active assets in the Gastroesophageal Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Incyte Corporation
Phase 1/2B
FLUOROURACILUM
Incyte Corporation
Phase 1/2B
Carboplatin
Iambic Therapeutics, Inc
Phase 1/2B
Cyclophosphamide
Diwakar Davar
Phase 2B
Pembrolizumab
Diwakar Davar
Phase 2B

View all 50 →

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →